Specific for ACR-modified protein (especially FDP-lysine type derivative).
Aufreinigung
Protein A purified
Klon
5F6
Isotyp
IgG1 kappa
Applikationshinweise
Recommended antibody concentration is 0.5-1.0 µg/mL on paraformaldehyde fixed tissue.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Frozen
Buffer
100 µg/mL antibody in 10mM PBS containing 0.1% NaN3 and 0.5% BSA
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C
Sugiyama, Sun, Nishinohara, Fujita, Masuda, Ochi, Takeuchi: "Expressions of lipid oxidation markers, N(ε)-hexanoyl lysine and acrolein in cisplatin-induced nephrotoxicity in rats." in: The Journal of veterinary medical science / the Japanese Society of Veterinary Science, Vol. 73, Issue 6, pp. 821-6, (2011) (PubMed).
Target
ACR-Modified Keyhole-Lympet Hemocyanine
Hintergrund
Acrolein (ACR) is a representative carcinogenic aldehyde found ubiquitously in the environment and formed endogenously through oxidation reactions, such as lipid peroxidation and myeloperoxidasecatalyzed amino acid oxidation. ACR is highly reactive aldehyde and reacts with lysine residue in protein. The reaction with ACR and lysine residue leads to the formation of numerous numbers of adducts, such as formyl-dehydropiperidino-lysine (FDP-lysine) type derivative. This antibody is specific for the ACR-modified protein, especially FDP-lysine type derivative.